Polyphor receives award of up to USD $3.3 million from Cystic Fibrosis Foundation to support clinical development of inhaled antibiotic murepavadin Award will help to fund planned Phase Ib/IIa study of inhaled murepavadin, a novel class antibiotic for the treatment of chronic Pseudomonas aeruginosa infections in cystic fibrosisDevelopment program...

Polyphor completes recruitment in Phase III trial of balixafortide in metastatic breast cancer ALLSCHWIL, Switzerland, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Polyphor AG (SIX: POLN) today announces that it has completed recruitment in its FORTRESS Phase III study of balixafortide in metastatic...

Polyphor receives CARB-X award of up to USD 18.44 million to support development of new antibiotic program ALLSCHWIL, Switzerland, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Polyphor AG (SIX: POLN), announced today that it has received a new and second non-dilutive funding award from CARB-X (Combating...

Polyphor Announces Closing of Fosun Pharma Licensing Agreement for balixafortide in China and Receipt of $15 Million Upfront Payment ALLSCHWIL, Switzerland, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Polyphor AG (SIX: POLN) today announced the closing of the previously announced exclusive licensing agreement with Fosun Pharma for...